In GH3/B6/F10 cells after estrogen washout, subsequent E2 or XE addition in the presence of Nifedipine could not elicit calcium influx. In rat pancreatic A-cells under basal conditions, Nifedipine reduced integrated calcium current compared with measurements before addition. In GH3/B6/F10 cells treated with E2 or XE, Nifedipine abolished estrogen-induced PRL secretion in the comparison with and without Nifedipine. [1,2]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Nifedipine and estrogen-stimulated calcium influx
Cell-based study · GH3/B6/F10 cells [1]
In GH3/B6/F10 cells, Nifedipine was added after estrogen washout. Subsequent E2 or XE addition in the presence of Nifedipine could not elicit calcium influx, compared with the E2- or XE-stimulated value.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM
- Exposure duration
- After washout of the estrogens; followed by a second addition of E2 or XE (10−8 M) in the presence of 10 μM Nifed
- Method
- added
- Co-treatment
- Other interventions in this design: E2 10−8 M; KCl 20 mM. Compound effect isolated by the comparison: E2- or XE-stimulated value.
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Nifedipine
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > Ca2+ measurements. (S11, S20, S21); Results > XE-induced Ca2+ influx is mediated by L-type Ca2+ channels. (S69, S70, S71); Figure 7 legend (S103, S104, S105); Figure 10 legend (S113)
change in fluorescence ratio divided by the basal fluorescence [(R – R0)/R0]: change in fluorescence ratio divided by the basal fluorescence [(R – R0)/R0]; comparator: E2- or XE-stimulated value — Results > XE-induced Ca2+ influx is mediated by L-type Ca2+ channels. (S71); Figure 7 legend (S105)
Nifedipine reduces integrated calcium current in rat pancreatic A-cells
Cell-based study · rat pancreatic A-cells [2]
Rat pancreatic A-cells received Nifedipine under basal conditions. Integrated calcium current decreased compared with measurements before addition.
Literature-Reported Treatment Conditions
- Treatment concentration
- 5 μM
- Exposure duration
- the interval between the depolarizations was 2 min
- Co-treatment
- Other interventions in this design: membrane depolarizations −70 to 0 mV. Compound effect isolated by the comparison: before and after addition.
- Reported limits
- Not stated in the sentences used: route, vehicle.
Methods and source locations
Compound reported in the paper: Nifedipine
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
materials and methods > Electrophysiology (S12, S19); materials and methods > Solutions (S20); results > Differential Dependence of Exocytosis on Ca2+ Influx through ω-Conotoxin-GVIA– and Nifedipine-sensitive Ca2+ Channels under Basal Conditions and after Activation of PKA (S115); Figure 1 legend (S122); Figure 8 legend (S170, S171, S172)
integrated Ca2+ current: integrated Ca2+ current; comparator: before and after addition — results > Differential Dependence of Exocytosis on Ca2+ Influx through ω-Conotoxin-GVIA– and Nifedipine-sensitive Ca2+ Channels under Basal Conditions and after Activation of PKA (S115); Figure 8 legend (S170)
Nifedipine and estrogen-induced PRL secretion
Cell-based study · GH3/B6/F10 cells; E2/Nifed (n = 32 samples/8 experiments) [1]
GH3/B6/F10 cells were treated with E2 or XE with and without Nifedipine. Nifedipine abolished E2- and XE-induced PRL secretion compared with the E2- or XE-treated value.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μM
- Exposure duration
- 3 min
- Method
- new DMEM/0.1% BSA with or without the appropriate reagent or vehicle control (ethanol) was added
- Vehicle
- ethanol
- Co-treatment
- Other interventions in this design: E2 10−8 M. Compound effect isolated by the comparison: with and without nifedipine.
Methods and source locations
Compound reported in the paper: Nifedipine
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Materials and Methods > PRL release and radioimmunoassay. (S24); Materials and Methods > Crystal violet assay. (S34); Results > PRL secretion is blocked by nifedipine. (S82, S83); Figure 10 legend (S113, S114, S115, S116)
percentage of the basal PRL secretion at each individual time point, normalized to the cell number [crystal violet (CV) signal]: percentage of the basal PRL secretion at each individual time point, normalized to the cell number [crystal violet (CV) signal]; comparator: E2- or XE-treated value — Results > PRL secretion is blocked by nifedipine. (S83); Figure 10 legend (S113, S115)
